This content is machine translated RMS and PPMS Early therapy with ocrelizumab slows the disease More than 100,000 people with MS are being treated with ocrelizumab worldwide. New analysis shows that drug exposure and low B-cell levels reduce the risk of progression. Long-term data advise…
View Post 4 min This content is machine translated ECTRIMS Congress in Berlin International MS experts provided an update on research and therapy How can Big Data be used in the field of multiple sclerosis? And what’s the latest on existing treatment options? The ECTRIMS congress in Berlin clarified.
View Post 9 min This content is machine translated Multiple Sclerosis (MS) News on monoclonal antibody therapy A widespread chronic disease, affecting a majority of young adults, causes a vehement financial and societal interest to develop effective and tolerable therapies. In 2017 alone, two new monoclonal antibodies…
